Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isophthalic Acid SCHEMBL27915628 | 0.81 | HCAR3 (0.55) | HCAR3NNMTFGFR4F10MEN1 | |
| SCHEMBL479494 | 0.79 | KDM4E (0.46) | HCAR3NNMTMTORPIK3CAMEN1 | |
| SCHEMBL30401857 | 0.79 | KDM4E (0.46) | HCAR3NNMTMTORPIK3CAMEN1 | |
| SCHEMBL503734 | 0.79 | HCAR3 (0.49) | HCAR3FGFR4PIK3CA | |
| SCHEMBL14097067 | 0.78 | MTOR (0.46) | HCAR3NNMTMTORPIK3CAGRM5 | |
| SCHEMBL4104898 | 0.76 | PTK2 (0.57) | FGFR4F10EGFRTDO2MAPT | |
| SCHEMBL503281 | 0.75 | MTOR (0.41) | HCAR3NNMTMTORPIK3CAGRM5 | |
| SCHEMBL4034322 | 0.73 | HCAR3 (0.51) | HCAR3 | |
| SCHEMBL483747 | 0.73 | FGFR4 (0.48) | HCAR3FGFR4F10MAPTMEN1 | |
| SCHEMBL2849198 | 0.73 | HCAR3 (0.51) | HCAR3FGFR4GRM5EGFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174884-B1 | 6,7-DIHYDROPYRAZOLO[1,5- ]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-26 | — | — | EP | disclosed |
| US-20180222908-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-09 | — | — | US | disclosed |
| US-20180222908-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-09 | — | — | US | disclosed |
| US-10017514-B2 | 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| US-20170267682-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-21 | — | — | US | disclosed |
| EP-2323992-B1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-20 | — | — | EP | disclosed |
| EP-2323992-B1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-20 | — | — | EP | disclosed |
| EP-2528903-B1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-20 | — | — | EP | disclosed |
| EP-2528903-B1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-20160199383-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-14 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| CN-1930144-A | 3-'4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMA (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-6800644-B2 | PHOSPHODIESTERASE-4 INHIBITOR, AMINOQUINOLINE OR AMINOISOQUINOLINE DERIVATIVES | EISAI CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20020055516-A1 | Nitrogen-containing heterocyclic compounds and medicaments containing the compounds | EISAI CO., LTD. | 2002-05-09 | — | — | US | disclosed |
| US-6352989-B1 | ENZYME INHIBITORS FOR PHOSPHODIESTERASE | EISAI CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-1052254-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055516-A1 | Nitrogen-containing heterocyclic compounds and medicaments containing the compounds | PDE4A, PDE4B, PDE5A | HCAR3 2124/4885NNMT 21/4885FGFR4 1273/4885 |
| US-20160199383-A1 | 5-ALKYNYL-PYRIMIDINES | MKI67, CCNA1, CCNT1 | HCAR3 2618/4885NNMT 852/4885FGFR4 276/4885 |
| US-10017514-B2 | 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors | GRM2, GRM5, GRM1 | HCAR3 180/4885NNMT 885/4885FGFR4 1552/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | HCAR3 900/4885NNMT 2620/4885FGFR4 1857/4885 |
| US-20170267682-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | HCAR3 167/4885NNMT 850/4885FGFR4 1484/4885 |
| US-20180222908-A1 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | HCAR3 167/4885NNMT 850/4885FGFR4 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.